Biotech Values

[caravon]

GT 1 treatment-experienced
(including 20.0 percent
(88/440) with cirrhosis)

SOF/LDV 12 weeks 93.6% (102/109)
SOF/LDV+RBV 12 weeks 96.4% (107/111)

SOF/LDV 24 weeks 99.1% (108/109)
SOF/LDV+RBV 24 weeks 99.1% (110/111)

Comments
- There are ~110 pts in each arm. Therefore, each patient contributes 1% to the overall count.
- Results are good indicating a superiority trend of a 24-weeks treatment regiment over a 12-week treatment. However again, statistical difference for this small sample trial is not that stat significant.